Shots:
- The CHMP has recommended Hopledo for the treatment of adults with Parkinson’s disease & mod. to sev. motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatments
- Opinion was based on the P-III (RISE-PD) trial assessing Hopledo in pts with Parkinson’s disease & mod. to sev. motor fluctuations, which showed a significant increase in Good ON time over immediate-release LD/CD with fewer daily doses
- Hopledo is an oral, modified-release formulation of levodopa/carbidopa designed for the treatment of fluctuations of Parkinson’s disease, with a phased EU launch planned from Oct 2026 following approval
Ref: Businesswire | Image: Zambon | Press Release
Related News: Acadia Pharmaceuticals’ Daybu (Trofinetide) Receives the CHMP Positive Opinion for Rett Syndrome
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
